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BACKGROUND and OBJECTIVES
• Teicoplanin is a highly plasma protein
bound glycopeptide antibiotic.
• Time-dependent bacterial killing with
persistent effects ~free(f)AUC/MIC.
• Trough (Cmin) therapeutic monitoring
is often used in clinical care.
• Critically ill children may present with
pathophysiological changes leading to
altered drug pharmacokinetics (PK)
and pharmacodynamics (PD).
• The objectives of this pilot study were:
(a) to document teicoplanin plasma
protein binding, and (b) to evaluate
target attainment rates using three
different PK/PD targets.
METHODS: study design
• (f)AUC was calculated using a non-
compartmental analysis based on the
log-linear trapezoidal rule with
PKSolver® (MS Excel).
• For first dose (f)AUC estimations, the
extrapolated (f)AUC to infinity was
taken into account (max. 20%).
• Correlation was assessed by means of
a scatter plot and Spearman’s Rank
Correlation Coefficient using SPSS®
Statistics version 24 (IBM, New York,
USA).
• Evaluated PK/PD targets included
AUC/MIC ≥ 750, fAUC/MIC ≥ 75
(assuming a MIC of 1 mg/L) and total
Cmin plasma concentration ≥ 10
mg/L.2,3
RESULTS
• Prospective observational PK study
• ICU children receiving teicoplanin
• Bolus dosing regimen: 10 mg/kg
every 12 h for 3 loading doses,
followed by 10 mg/kg once daily.
• Blood samples were collected during




• Free plasma concentrations were
separated at 37 °C using a validated
ultrafiltration method.1
• Free and total teicoplanin plasma
concentrations were determined
using a validated reversed-phase
HPLC method.1
• Variable PK
• Plasma protein binding
 saturable and variable
 ≈ adults1
• Significant underdosing
• Variability in target attainment
rates : fAUC/MIC<AUC/MIC<Cmin
CONCLUSIONS
For additional information: mail to pieter.decock@uzgent.be
Table 1. Patient, treatment, sampling and PK characteristics
Figure 1 : Plasma protein binding
Figure 2: Target attainment : Cmin vs. AUC/MIC
Figure 3: Target attainment : AUC/MIC vs. fAUC/MIC
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PATIENT CHARACTERISTICS No. (%) / Median (IQR)
Gender (male/female) 15/12 (56/44)
Age (years) 2.2 (0.8-4.8)
Weight (kg) 12.0 (8.4-18.5)
Serum albumin (g/L) 30 (27-33)
Total protein (g/L) 51 (47-60)
TREATMENT CHARACTERISTICS No. (%)
Empirical start 17 (63)
SAMPLING CHARACTERISTICS No. (%) / Median (IQR)
Number of collected samples 130
Collected samples per dose interval 5 (5-5)
Collected total trough samples 27
PK Median (IQR)
AUC (mg x h/L) 823 (702-949)
fAUC (mg x h/L) 72 (55-86)
Cmin (mg/L) 16.0 (10.3-17.9)
Intrapatient median difference between
lowest and highest free fraction (range):
4.0% (1.5-13.4%) 
